Transcriptomic Characterization Of Endometrial Cancer In Order To Find New Therapeutic Targets.

e17113 Background: There are unmet needs for targeted therapy in Endometrial Cancer (EC). The integrated genomic characterization of EC provided insights into disease biology. Our primary objective is to identify potential actionable pathways to target therapeutically in EC according to the microsatellite status (microsatellite instability high = MSI-H, and microsatellite stable/microsatellite instability low = MSS/MSI-L). Methods: 375 RNAs from the genomic profile of EC within the TCGA database were used to perform RNA-seq analysis. We analyzed RNA-sequencing data with edgeR package to filter and normalize the data, followed by the limma package with its Voom method, linear modeling and empirical Bayes moderation to asses differential expression. Reactome FI Cytoscape app was used to perform pathway and network-based data analysis. Results: According to the microsatellite status, two groups were identified: Group 1 = MSI-H (127 patients) and Group 2 = MSS/MSI-L (248 patients). Significant expression differences were found in 2141 genes. In the Group 1 we identified 1194 genes overexpressed and 947 genes overexpressed in the Group 2. Group 1 includes genes associated with cell proliferation. Group 2 includes genes associated with genomic instability and apoptosis evasion (table 1). Conclusions: In EC patients, Cyclin-dependent kinase (CDK) pathways could be a potential therapeutic target, especially in patients with MSI-H tumors. Further studies are necessary in order to evaluate the activity of CDKs inhibitors in this population.[Table: see text]